Vinita Kothari
Family · Los Alamitos, CANPI 1417428731
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,237, 2.5 times the $910 reported in 2021. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 75 payments — averaging $85.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Vanda Pharmaceuticals Inc.$494
- GSK$348
- Abiomed$253
- Teva Pharmaceuticals USA, Inc.$252
- Alnylam Pharmaceuticals Inc.$244
- plus $4K from 27 others
What the payments were for
- Food & beverage$6,389100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 28 | $1,064 |
| Vanda Pharmaceuticals Inc. | 4 | $494 |
| GSK | 3 | $348 |
| Abiomed | 2 | $253 |
| Teva Pharmaceuticals USA, Inc. | 2 | $252 |
| Alnylam Pharmaceuticals Inc. | 2 | $244 |
| Argenx US, Inc. | 2 | $241 |
| Axsome Therapeutics, Inc. | 2 | $241 |
| Amgen | 2 | $239 |
| Neurocrine Biosciences, Inc. | 2 | $236 |
| Ultragenyx Pharmaceutical Inc. | 2 | $227 |
| Biogen | 2 | $208 |
| Cvrx, Inc. | 1 | $151 |
| Sanofi | 1 | $149 |
| Boston Scientific | 2 | $143 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $130 |
| AstraZeneca | 1 | $125 |
| Edwards Lifesciences | 1 | $125 |
| Neurelis, Inc. | 1 | $125 |
| AMAG Pharmaceuticals, Inc. | 1 | $125 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $125 |
| Amylyx Pharmaceuticals, Inc. | 1 | $122 |
| Otsuka America Pharmaceutical, Inc. | 1 | $120 |
| Astellas Pharma US Inc | 1 | $118 |
| Boehringer Ingelheim | 1 | $117 |
| Tactile Systems Technology Inc | 1 | $107 |
| Johnson & Johnson | 1 | $106 |
| Gilead | 1 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $89 |
| Alkermes, Inc. | 1 | $88 |
| Gen-probe Sales & Service, Inc. | 1 | $86 |
| Stryker | 1 | $77 |
| TG Therapeutics, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,389 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 27 | $259 |
| Doxycycline Monohydrate | 20 | $195 |
| Paxlovid (Eua)Nirmatrelvir/Ritonavir | 11 | $187 |
| Prednisone | 15 | $127 |
| PaxlovidNirmatrelvir/Ritonavir | 26 | $0 |
Paid to pharmacies, not to this prescriber.
Other family in Los Alamitos
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
- Gabriel SchwartzSan Francisco$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.